Gilead Pharmaceuticals reported a 15 percent increase in second-quarter revenues, fueled by higher sales of its HIV antiviral drugs.
The company, which has operations in Branford, brought in $2.77 billion in revenue, most of it product sales. That was up from $2.41 billion during the same quarter a year ago.
Profits were $772.6 million, up 9 percent.
Sales of Complera/Eviplera were up 159 percent to $188.7 million while Stribild, which launched in the third quarter of 2012, added $99.4 million of new Q2 revenue.
Gilead's biggest seller, Atripla, brought in 4 percent more revenue at $938.1 million.
Product sales were up 20 percent in the United States and 4 percent in Europe.